Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Merck & Co. reveals new agents for BPH

Dec. 10, 1996

VIP analogs and derivatives claimed for smooth muscle relaxation

Dec. 9, 1996

Sepracor gets go-ahead for U.S. clinical trials on (S)-oxybutynin

Dec. 6, 1996

Synsorb Pk licensed to major Japanese pharmaceutical company

Dec. 4, 1996

Chugai starts phase I clinical trials with phosphate binder

Dec. 4, 1996

Negative clinical results reported for aromatase inhibitor in BPH

Nov. 29, 1996

Kissei begins overseas development of BPH treatment agent

Nov. 21, 1996

Kyorin claims cholinergic agents

Nov. 21, 1996

Glaxo Wellcome claims 5alpha-reductase inhibitors for BPH

Nov. 19, 1996

OP-1 effective in renal failure

Nov. 15, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...